Aquantia Deliverables and Milestones Sample Clauses

Aquantia Deliverables and Milestones. The table below represents a summary of the Aquantia & Intel deliverables, milestones, and associated delivery dates. [*]. Section Reference Owner(s) Deliverable/Milestone Date (commit) 1 Aquantia [*] [*] 2 Aquantia [*] [*] 3 Intel [*] [*] 4 Aquantia [*] [*] 5 Aquantia [*] [*] 6 Aquantia [*] [*] 7 Intel [*] [*] 8 Intel [*] [*] 9 Intel [*] [*] 10 Aquantia [*] [*] 11 Intel [*] [*] 12 Aquantia [*] [*] 13 Aquantia [*] [*] 14 Intel [*] [*] 15 Aquantia [*] [*] 16 Aquantia [*] [*] 17 Aquantia [*] [*] 18 Aquantia [*] [*] 19 Intel [*] [*] [*]. Checkpoints with Aquantia date checkpoint content [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] Milestone Definition Section Ref Deliverable/ Milestone Milestone Definition [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*1 page*] AQUANTIA INTEL CORPORATION By: /s/ Faraj Aalaei By: /s/ Dawn Moore Printed Name: Faraj Aalaei Printed Name: Dawn Moore Title: CEO GM, LAN Access Division Date: 8/17/12 Date: 8/20/12 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. ATTACHMENT #3 TO [*] PRODUCT PROJECT STATEMENT Quality and Reliability CONFORMANCE REQUIREMENTS Sample Size May Change Per Risk Assessment These Q&R requirements may be adjusted, upon due consideration by both Intel and Aquantia at a peer-to-peer level, or by formal re-negotiation and written acceptance, if so required. [*]. [*] Requirements [*] Stress [*] Requirement [*] Notes [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] Q&R Requirements Stress Lots Total Units/Lot QS Requirement PRQ Requirement Notes [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] Notes: [*6 pages*] [*] By/ Between [*] Intel/Aquantia [*] Intel/Aquantia [*] Intel/Aquantia [*1 page*] AQUANTIA INTEL CORPORATION By: /s/ Faraj Aalaei By: /s/ Dawn Moore Printed Name: ...
Aquantia Deliverables and Milestones. The table below represents a summary of the Aquantia and Intel deliverables, milestones, and associated delivery dates. [*]. Each milestone is briefly defined in the section below the table. [*]. Section Ref Deliverable/Milestone Owner(s) Date (DATES TBD, WILL CHANGE!)

Related to Aquantia Deliverables and Milestones

  • Milestones Subject to the provisions of the SGIP, the Parties shall agree on milestones for which each Party is responsible and list them in Attachment 4 of this Agreement. A Party’s obligations under this provision may be extended by agreement. If a Party anticipates that it will be unable to meet a milestone for any reason other than a Force Majeure event, it shall immediately notify the other Parties of the reason(s) for not meeting the milestone and (1) propose the earliest reasonable alternate date by which it can attain this and future milestones, and (2) requesting appropriate amendments to Attachment 4. The Party affected by the failure to meet a milestone shall not unreasonably withhold agreement to such an amendment unless it will suffer significant uncompensated economic or operational harm from the delay, (1) attainment of the same milestone has previously been delayed, or (2) it has reason to believe that the delay in meeting the milestone is intentional or unwarranted notwithstanding the circumstances explained by the Party proposing the amendment.

  • Development Milestones (a) Alnylam, its Affiliates or sublicensees (except Naked Sublicensees) will pay to Isis the following milestone payments for each Alnylam Product within [**] after the first achievement of each of the following events: MILESTONE EVENT MILESTONE PAYMENT --------------- ----------------- Initiation of Phase I Trial US$[**] Initiation of Phase III Trial US$[**] Filing NDA US$[**] Marketing Approval US$[**] Each milestone payment under this Section 7.3(a) will only be due on the [**] Alnylam Product that modulates a particular Gene Target to trigger such milestone payment, whether such milestone is achieved by Alnylam or an Affiliate or sublicensee of Alnylam.

  • Deliverables Upon satisfactory completion of the work authorization, the Engineer shall submit the deliverables as specified in the executed work authorization to the State for review and acceptance.

  • Project/Milestones Taxpayer provides refrigerated warehousing and logistic distribution services to clients throughout the United States. In consideration for the Credit, Taxpayer agrees to invest in a new refrigeration and distribution facility in the McClellan Park area of Sacramento, California, and hire full-time employees (collectively, the “Project”). Further, Taxpayer agrees to satisfy the milestones as described in Exhibit A (“Milestones”) and must maintain Milestones for a minimum of three (3) taxable years thereafter. In the event Taxpayer employs more than the number of full-time employees, determined on an annual full-time equivalent basis, than required in Exhibit A, for purposes of satisfying the “Minimum Annual Salary of California Full-time Employees Hired” and the “Cumulative Average Annual Salary of California Full-time Employees Hired,” Taxpayer may use the salaries of any of the full-time employees hired within the required time period. For purposes of calculating the “Minimum Annual Salary of California Full-time Employees Hired” and the “Cumulative Average Annual Salary of California Full-time Employees Hired,” the salary of any full-time employee that is not employed by Taxpayer for the entire taxable year shall be annualized. In addition, the salary of any full-time employee hired to fill a vacated position in which a full-time employee was employed during Taxpayer’s Base Year shall be disregarded.

  • SCHEDULE AND MILESTONES The planned major milestones for the activities for this Annex defined in the "Responsibilities" Article are as follows:

  • Project Deliverables The Contractor shall provide each of the following deliverables in writing to the City for review and approval to achieve the project objectives.

  • Regulatory Milestones In partial consideration of the rights granted by Lightlake to Adapt hereunder and subject to the terms and conditions set forth in this Agreement, Adapt shall pay to Lightlake a milestone payment within thirty (30) days after the achievement of each of the following milestones:

  • Development Milestone Payments Lilly shall pay to Hutchison the Development milestone payments listed below as follows: (i) [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. within thirty (30) days of the earlier of the date of FTO Submission and Lilly’s election not to terminate this Agreement pursuant to Article 7.1(c) if the relevant milestone event occurs before such earliest date; or (ii) within thirty (30) days of the milestone event if the relevant milestone event occurs after the date of FTO Submission or Lilly’s election not to terminate this Agreement pursuant to Article 7.1(c). Each milestone shall be payable only once upon the first occurrence of the described event for any Product. Milestone Event Milestone Payment [**] [**] [**] [**] [**] [**] [**] [**]

  • Sales Milestones Pfizer shall pay to CytomX the following one-time payments (each, a “Sales Milestone Payment”) when aggregate Annual Net Sales of a Licensed Product in the Territory in a Pfizer Year first reach the respective threshold (a “Sales Threshold”) indicated below (each, a “Sales Milestone”); provided that such Sales Threshold with respect to a Licensed Product must be reached within the first seven (7) full Pfizer Years following the First Commercial Sale of such Licensed Product in the United States. Total Annual Net Sales Sales Milestone Payment for Licensed Products Targeting EGFR Sales Milestone Payment for Licensed Products Targeting the Second Target or a Replacement Target Sales Milestone Payment for Licensed Products Targeting an Additional Target Total Annual Net Sales exceeding $500,000,000 [***] [***] [***] Total Annual Net Sales exceeding $1,000,000,000 [***] [***] [***] Total Annual Net Sales exceeding $2,000,000,000 [***] [***] [***] Total Annual Net Sales exceeding $3,000,000,000 [***] [***] [***] ***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. If more than one unmet Sales Threshold is achieved with respect to the same Pfizer Year, payment will be made with respect to the higher or highest Sales Threshold achieved in such Pfizer Year and all other previously unmet Sales Thresholds achieved with respect to such Pfizer Year will remain eligible to be met in future Pfizer Years. Any Sales Milestone Payment with respect to any Pfizer Year shall be payable within sixty (60) days of the end of such Pfizer Year in the United States. Each Sales Milestone Payment is payable a maximum of one time only, regardless of the number of Licensed Products that achieve a particular Sales Threshold.

  • Commercial Milestones In partial consideration of the rights granted by MedImmune to Licensee hereunder, Licensee shall pay to MedImmune the following payments, which shall be nonrefundable, noncreditable and fully earned upon the achievement of the applicable milestone event: